儿童重症哮喘靶向治疗研究新进展  

New Progress in Targeted Therapy of Severe Asthma in Children

作　　者：吴莎 朱晓萍[1,2] WU Sha;ZHU Xiaoping(Guizhou Medical University,Guiyang 550004,China;Department of Pediatrics,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学,贵阳550004 [2]贵州医科大学附属医院儿科,贵阳550004

出　　处：《医学综述》2023年第20期4108-4113,共6页Medical Recapitulate

基　　金：贵州省科技计划项目(黔科合支撑〔2020〕4Y124号)。

摘　　要：支气管哮喘(简称哮喘)是儿童最普遍的慢性疾病之一,部分患儿以最大程度治疗仍无法控制。随着研究的进展,人们对哮喘潜在发病机制了解不断增加,靶向治疗是基于对疾病的免疫学机制的识别,对每个儿童实施精准治疗,已有大量临床试验证实相关生物靶向治疗药物的有效性及安全性。目前批准的生物制剂主要针对高T2型炎症通路,可有效降低哮喘发作的频率、控制症状和减少全身性类固醇的使用等,但低T2型哮喘尚缺乏有效的靶向药物。未来应对儿童靶向生物治疗进行单独的高质量研究,以测试其对于儿童的疗效和安全性。Bronchial asthma(short for asthma)is one of the most common chronic diseases in children,and some children′s conditions cannot be controlled with maximum treatment.As research progresses,understanding of the underlying mechanisms of asthma continues to increase.Targeted therapy is based on the recognition of the immunological mechanism of the disease to implement precision treatment for each child,and a large number of clinical trials have confirmed the effectiveness and safety of relevant biological targeted therapeutic drugs.Currently approved biologics are mainly targeted at high-T2 inflammatory pathways,which can effectively reduce the frequency of asthma attacks,control symptoms and reduce the use of systemic steroids,etc.,but there is still a lack of effective targeted drugs for low-T2 asthma.Separate high-quality studies of targeted biotherapeutics in children should be conducted in the future to test their efficacy and safety for children.

关 键 词：哮喘 儿童 靶向治疗 

分 类 号：R725.6[医药卫生—儿科]